Cardiac prosthesis

Information

  • Patent Grant
  • 12318295
  • Patent Number
    12,318,295
  • Date Filed
    Monday, November 21, 2022
    2 years ago
  • Date Issued
    Tuesday, June 3, 2025
    28 days ago
Abstract
Systems, devices, and methods for adjusting cardiac tissue are described involving adjustment of a frame element of an implantable device relative to the cardiac tissue. At least a component of the implantable device is rotated relative to the cardiac tissue and/or another component of the implantable device. At least a component of the implantable device is axially movable relative to the cardiac tissue and/or another component of the implantable device.
Description
FIELD

This disclosure relates generally to cardiac treatment devices and techniques, and in particular, to methods and devices for repair of mitral valve defects such as mitral valve regurgitation.


BACKGROUND

The mitral valve is one of four heart valves that direct blood through the two sides of the heart. The mitral valve itself consists of two leaflets, an anterior leaflet and a posterior leaflet, each of which are passive in that the leaflets open and close in response to pressure placed on the leaflets by the pumping of the heart.


Among the problems that can develop or occur with respect to the mitral valve is mitral valve regurgitation (MR), in which the mitral valve leaflets become unable to close properly, thus causing leakage of the mitral valve. Severe mitral regurgitation is a serious problem that, if left untreated, can adversely affect cardiac function and thus compromise a patient's quality of life and life span.


Currently, mitral regurgitation is diagnosed by many indicators, and the mechanism of mitral regurgitation can be accurately visualized by trans-esophageal echocardiography or fluoroscopy with dye injection. The most prevalent and widely accepted current technique to correct mitral regurgitation is to repair the mitral valve via open-heart surgery while a patient's heart is stopped and the patient is on cardiopulmonary bypass, a highly invasive procedure that has inherent risks.


SUMMARY

In one aspect, a method is described comprising inserting an implant proximate a mitral valve, the implant comprising a tubular body and a plurality of piercing members, the tubular body comprising an upper (i.e. proximal) diameter and a lower (i.e. distal) diameter. The method also includes engaging tissue proximate the mitral valve by the plurality of piercing members and transitioning the tubular body from a first structural configuration to a second structural configuration by application of an expansive force to the tubular body proximate the upper diameter, the first structural configuration having the upper diameter smaller than the lower diameter and the second structural configuration having the upper diameter larger than the lower diameter.


In another aspect, an implant is described comprising a tubular body comprising an upper diameter and a lower diameter, the tubular body having a first structural configuration in which the upper diameter is smaller than the lower diameter and a second structural configuration in which the upper diameter is larger than the lower diameter, the tubular body configured to transition from the first structural configuration to the second structural configuration by application of an expansive force to the tubular body proximate the upper diameter. The implant also comprises a plurality of piercing members connected to the tubular body and proximate the lower diameter to engage tissue proximate a mitral valve.


In another aspect, a system is described comprising a guide wire, a sheath over the guide wire, and an implant for delivery to a body by traveling through the sheath and along the guide wire. The implant comprises a tubular body comprising an upper diameter and a lower diameter, the tubular body having a first structural configuration in which the upper diameter is smaller than the lower diameter and a second structural configuration in which the upper diameter is larger than the lower diameter, the tubular body configured to transition from the first structural configuration to the second structural configuration by application of an expansive force to the tubular body proximate the upper diameter. The implant also comprises a plurality of barbs connected to the tubular body and proximate the lower diameter to penetrate tissue proximate a mitral valve.


In another aspect, a delivery system for delivering an implant within the heart for reducing the size of a heart valve annulus is described. The delivery system comprises a plurality of rotatable drivers and the implant. The plurality of rotatable drivers is configured to extend through one or more lumens of the delivery system. The implant is configured for delivery within the heart by traveling through the one or more lumens of the delivery system. The implant comprises a tubular body and a plurality of helical anchors. The tubular body comprises a frame defining a proximal diameter and a distal diameter. The tubular body has a first structural configuration in which the proximal diameter is smaller than the distal diameter and a second structural configuration in which the proximal diameter is larger than the distal diameter. The plurality of helical anchors are connected to the tubular body proximate the distal diameter of the frame. The plurality of helical anchors are configured to be rotated by the rotatable driver to advance the plurality of helical anchors distally relative to the frame and penetrate the heart valve annulus.


In some embodiments of the delivery system, the implant may further comprise a series of distal apices and a series of holes. The series of distal apices may be formed by the frame proximate the distal diameter. The series of holes may be in each of the distal apices and are sized and spaced to receive therethrough a corresponding helical anchor for rotational engagement of the distal apex by the corresponding helical anchor. The plurality of rotatable drivers and the implant may be configured for transcatheter delivery of the implant to the heart. The delivery system may further comprise a delivery catheter comprising the one or more lumens of the delivery system. A distal end of the delivery catheter may be configured to advance through an opening in the femoral vein, through the femoral vein and into the right atrium of the heart, and through the septum of the heart into the left atrium. The delivery system may further comprise a location ring configured to be located on a side of the heart valve opposite the implant and to couple with the implant. The location ring may be separate from the implant and configured to be located on a side of the heart valve opposite the implant to assist in positioning the implant. The location ring may be configured to be removed from the heart after the implant is positioned and the plurality of helical anchors penetrate the heart valve annulus. The delivery system may comprise one lumen configured to receive therethrough an intracardiac echo catheter for visualizing a position of the implant relative to the mitral valve annulus. The delivery system may further comprise the intracardiac echo catheter. The implant may further comprise an expandable tubular member coupled with a proximal end of the frame and configured to expand to increase the proximal diameter of the frame. The expandable tubular member may be integral with the frame.


In another aspect, an implant for reducing the size of a heart valve annulus is described. The implant comprises a tubular body and a plurality of helical anchors. The tubular body comprises a frame defining a proximal diameter and a distal diameter. The tubular body has a first structural configuration in which the proximal diameter is smaller than the distal diameter and a second structural configuration in which the proximal diameter is larger than the distal diameter. The plurality of helical anchors are connected to the tubular body proximate the distal diameter of the frame. Each of the plurality of helical anchors is configured to be rotated by a plurality of rotatable drivers through a series of holes in lower apices of the frame to advance the plurality of helical anchors distally relative to the frame and penetrate the heart valve annulus.


In some embodiments, the implant further comprises an expandable tubular member proximate a proximal end of the frame, wherein when force is applied to the expandable member, the expandable member expands and engages the proximal end of the frame causing the frame to invert from the first structural configuration to the second structural configuration. The expandable tubular member may be integral with the proximal end of the frame. The expandable tubular member may be a stent-like member positioned internally of the frame proximate the proximal diameter of the frame. The implant may be configured to be contracted to a delivery configuration for transcatheter delivery of the implant to the heart by a delivery system. The implant may further comprise an expandable tubular member coupled with a proximal end of the frame, wherein contracting the expandable tubular member for transcatheter delivery causes the proximal diameter of the frame to decrease relative to an unconstrained state, which causes the distal diameter of the frame to increase relative to the unconstrained state such that the proximal and distal diameters of the frame are approximately the same when delivered. The implant may further comprise angled segments of the frame forming distal apices of the frame proximate the distal diameter, and the series of holes in each of the distal apices may be sized and spaced to receive therethrough a corresponding helical anchor for rotational engagement of the distal apex by the corresponding helical anchor. The tubular body may be configured to transition from the first structural configuration to the second structural configuration by application of an expansive force to the tubular body proximate the proximal diameter.





BRIEF DESCRIPTION OF THE DRAWINGS

For a more complete understanding of the present disclosure and its features and advantages, reference is now made to the following description, taken in conjunction with the accompanying drawings, in which:



FIGS. 1A-1F illustrate an example embodiment of an implant in accordance with the present disclosure;



FIGS. 2A-2D illustrate an alternative example embodiment of an implant in accordance with the present disclosure;



FIGS. 3A-3B illustrate a further alternative example embodiment of an implant in accordance with the present disclosure;



FIGS. 4A-4B illustrate an additional example embodiment of an implant in accordance with the present disclosure;



FIG. 5 illustrates examples of delivery routes of an implant, in accordance with the present disclosure;



FIG. 6 illustrates an example embodiment of the present disclosure utilizing vibrations, in accordance with the present disclosure;



FIG. 7 illustrates an alternative example embodiment of the present disclosure utilizing vibrations, in accordance with the present disclosure; and



FIG. 8 illustrates an additional example embodiment of the present disclosure utilizing vibrations, in accordance with the present disclosure.



FIGS. 9A-9B are perspective views of other embodiments of implants having rotatable helical anchors for securing the implants to a valve annulus.



FIG. 10-12 are perspective views of another embodiment of an implant, having an expandable tubular element, and configured to be secured to a valve annulus with helical anchors.



FIG. 13 is a perspective view of an embodiment of a delivery system shown delivering an embodiment of the implant of FIGS. 10-12.



FIG. 14 is a perspective view of an embodiment of a delivery system shown delivering the implant of FIG. 9A.



FIGS. 15A-15D are sequential views of an embodiment of a transcatheter delivery system for delivering the implant of FIG. 9A showing an embodiment of a method for the delivery, positioning and anchoring of the implant.





DETAILED DESCRIPTION

The present disclosure relates to an implant including a tubular body and piercing members for reshaping a mitral valve suffering from mitral regurgitation. The implant may include two or more structural configurations. In a first structural configuration, an upper, i.e. proximal, diameter (away from the mitral valve) may be smaller than a lower, i.e. distal, diameter (proximate the mitral valve). In this first structural configuration, the piercing members of the implant may engage the tissue proximate the mitral valve, for example, the mitral valve annulus. The implant may then be transitioned from the first structural configuration to a second structural configuration in which the size of the upper diameter is larger than the lower diameter. This may be facilitated by an expansive force causing the upper diameter to expand, in turn causing the lower diameter to contract. As the lower diameter contracts, the penetrating members engaged with the tissue proximate the mitral valve may cause the mitral valve to also contract to a smaller diameter. This may allow the valve leaflets to close properly, addressing mitral regurgitation.



FIGS. 1A-F illustrate one embodiment of an implant. For example, as shown in FIG. 1A, in some embodiments, repair of a mitral valve may be achieved by a catheter system and catheterization procedure, wherein a catheter may be configured for percutaneous access to the mitral valve through the left ventricle. Access may be granted to the left ventricle through the apex of the heart where an incision may be made to insert a dilator and sheath 150 for access of a repair catheter 140. Sheath 150 may measure about six French to about thirty French and a closure device may be used in conjunction with the entry of this access catheter 140.


In one embodiment of the present disclosure, catheter 140 may include an extendable guide wire assembly 160, which may guide the system into position. Guide wire 160 may measure between 0.010 inches and 0.038 inches in diameter, and may be 0.035 inches in diameter. Catheter 140 or sheath 150 when accessed through the apex of the heart may measure about twenty to thirty centimeters in length.


As shown in FIG. 1B, once access has been achieved, a delivery system may be introduced through sheath 150 along guide wire 160 with implant 110 for reducing the diameter of the mitral valve annulus. Catheter 140 may deliver implant 110 to resize the mitral valve to reduce the mitral valve cross sectional area or move the posterior leaflet back into position limiting or reducing mitral valve regurgitation.


Implant 110 may include a tubular body with portions of the tube removed similar to a stent structure where a portion of the material may be removed via laser cutting or other means to selectively cut portions of the tube away forming a radially-expandable tubular body.


Implant 110 may be introduced in a collapsed structural configuration. This collapsed structural configuration may allow implant 110 to fit within sheath 150 to allow for a percutaneous procedure rather than an open-heart procedure. As shown in FIG. 1B, once implant 110 arrives in the left atrium, implant 110 may be expanded to a larger first structural configuration to engage tissue proximate the mitral valve, for example, the mitral valve annulus. In one embodiment, implant 110 may have a tubular shape with a free diameter of about twenty five to about thirty five millimeters in diameter, a height of about ten to about thirty millimeters, and a wall thickness of between about 0.005 inches and about 0.040 inches. Implant 110 may be constructed of a metallic material such as stainless steel, MP35N alloy, Nitinol or other implantable material.


In some embodiments, implant 110 may be tapered such that one end may be larger in diameter than the other end, appearing generally frustoconical in shape. The diameters of the ends may be approximately twenty five millimeters on the smaller end and approximately thirty five millimeters on the larger end. Implant 110 may also be non-circular where a portion of the implant may be elliptical or include a radial portion that is flat. This flat portion may be oriented toward the aortic valve and the circular portion may be positioned toward the posterior leaflet. To facilitate discussion of implant 110, an upper portion and lower portion may be described. The lower portion may refer to the end of implant 110 proximate mitral valve 170 while the upper portion may refer to the end of implant 110 free in the left atrium.


Implant 110 may include piercing members 115 proximate the lower portion of implant 110 proximate mitral valve 170 to engage with tissue proximate mitral valve 170, for example, the mitral valve annulus. Piercing members 115 may include barbs or hooks similar to fish hook barbs or other similar feature to resist withdrawal from tissue once pierced. Piercing members 115, barbs or hooks of the piercing members 115, or any combination thereof may pierce the tissue to engage with the tissue. Piercing members 115 may include a singular barb or hook, or a plurality of barbs or hooks per piercing member 115. Piercing members 115 may be immediately exposed or covered for delivery. They may number from one to fifty and may have a length of about four to twenty millimeters in length. They may have the same wall thickness as a wall of the tubular body of implant 110 or may differ with an increased or decreased thickness or taper in either direction to allow for mechanical integrity.


Piercing members 115 of implant 110 may be integral or attached to implant 110 as a secondary component glued, welded, or attached as an ancillary part. Piercing members 115 may also be laser cut into implant 110, and therefore attached to implant 110. The barbs or hooks may be fatigue resistant from fracture or separation from piercing members 115. For example, the barbs or hooks may have additional strength or wall thickness at the connection to piercing members 115. The barbs or hooks may also be attached with a hinged attachment allowing motion relative to the heart, but not longitudinally where the barbs or hooks may separate from piercing member 115.


The barbs or hooks of piercing member 115 may be active or passive meaning that the barbs or hooks may be activated with heat to bend or expose or mechanically formed through an external force to bend or expose. For example, each barb or hook may be sheathed inside a tube and removal of this tube may allow the barb or hook to be activated by, for example, body heat or some other activation factor, such that the barb or hook is exposed so as to engage the surrounding tissue. In a passive configuration, the barbs or hooks may be static in nature and either always exposed or exposed as soon as a covering is removed. The barbs or hooks may be hidden until deployment limiting the exposure during delivery and positioning and only exposed once positioning is finalized. The exposure may be completed as individual barbs or as multiples of barbs. In some embodiments, the covering is thus only a temporary covering.


As shown in FIG. 1B, in some embodiments, implant 110 may be positioned at the annulus of mitral valve 170 where the mitral valve hinge meets the left ventricle and the left atrium meets mitral valve 170. Positioning implant 110 at this location may be facilitated using a location ring 120. For example, location ring 120 may be positioned within the left ventricle, under mitral valve 170. A catheter to deliver location ring 120 may be placed in the left ventricle via the same access point through sheath 150. In some embodiments, a catheter 130 may extend through the aorta to deliver and/or remove the location ring 120. The catheter 130 as shown may extend through the aorta and through the aortic valve, and enter the left ventricle. In some embodiments, the location ring 120 may be delivered and/or removed from the apical entry point, as mentioned, or from trans-aortic entry via a femoral entry. In some embodiments, location ring 120 may comprise a metallic ring or coiled section, which may be viewed via fluoroscopy or echo guidance to confirm the location of location ring 120. This may allow confirmation of a positive location for implant 110 to be located with respect to the mitral valve annulus. In addition to the use of a location ring, other methods for determining a desired location to attach implant 110 may could include echo guidance, CT, fluoroscopy or MRI other imaging techniques to highlight the mitral valve hinge.


As shown in FIG. 1C, while in a first expanded structural configuration, and once a proper position has been achieved, implant 110 may have a downward force “A” applied to cause piercing members 115 to engage with and/or pierce the mitral valve annulus. This force may be applied by the delivery system itself, or may be applied by a secondary catheter that may be introduced for engaging piercing members 115 with the tissue proximate mitral valve 170.


As shown in FIG. 1D, the location ring 120 may be used to locate the relative position of the implant 110 after anchoring the implant 110 to the annulus. For example, the location ring 120 may comprise a metallic ring or coiled section, which may be viewed via fluoroscopy or echo guidance to confirm the location of location ring 120 and implant 110. After confirmation of acceptable placement of the implant 110, or after inversion of the implant 110 as described below, the location ring 120 may then be removed. Thus, the location ring 120 may be temporary. The location ring 120 may thus be separate from the implant 110 and configured to be located on a side of the heart valve opposite the implant 110 to assist in positioning the implant 110. The location ring 120 may be configured to be removed from the heart after the implant 110 is positioned and the plurality of helical anchors penetrate the heart valve annulus. The location ring 120 may be removed by the same delivery system by which it was inserted, for example the delivery system shown in FIGS. 1A-1F, the catheter 130, etc.


In some embodiments, location ring 120 may also act as an anchor for implant 110. In such an embodiment, implant 110 above mitral valve 170 (i.e. in the left atrium side of mitral valve 170) may attach to location ring 120 below mitral valve 170 (i.e. in the left ventricle side of mitral valve 170). For example, the hooks or barbs of piercing members 115 may engage with location ring 120. This may be accomplished by a through suture, a barbed means, wrapping or clipping location ring 120 to implant 110. Magnetic forces may also hold location ring 120 and implant 110 together either temporarily or permanently. Alternatively, the hooks or barbs may also be attached to some other separate implant below mitral valve 170 in the left ventricle. This may be a wire, ring, or tee anchor to secure implant 110 to via wires, threads or mechanical means to attach through the tissue median. For convenience, this implant below mitral valve 170 may be referred to as location ring 120, even if not used in locating implant 110 proximate mitral valve 170.


In some embodiments, the shape of location ring 120 may be a circular cross section measuring about 0.010 inches to about 0.090 inches in diameter and may encircle the mitral annulus. The shape may also be non-circular, oval, biased to one axis or multi-axis to accommodate the multi-plane shape of mitral valve 170, which is more saddle shaped. It may also have a variable stiffness in different sections to accommodate tighter bends in the placement of location ring 120. Location ring 120 and or a delivery catheter may also be steerable to navigate the area under mitral valve 170 for ease of placement. Utilizing push pull wires to compress or load portions of the catheter or location ring 120 to predictably bend and orient the catheter or location ring 120 may allow a user to access difficult anatomical features en route to and around mitral valve 170.


As shown in FIG. 1E, once piercing members 115 have engaged the tissue proximate mitral valve 170, for example, the mitral valve annulus, an expansive force “B” may be applied to the upper portion of implant 110. By applying expansive force “B” to implant 110, a reactive reducing force “C” may also be produced at the lower portion of implant 110. As the diameter of the lower portion is decreased from reactive reducing force “C,” the diameter of mitral valve 170 is also reduced due to the attachment of implant 110 to the tissue around mitral valve 170. For example, once a sufficient reducing force “C” has been generated to reshape mitral valve 170 to a desired size, implant 110 may be left in a final position in which the size change of mitral valve 170 may be maintained. This may be a second structural configuration.


As shown in FIG. 1F, in some embodiments, piercing members 115 may engage the tissue proximate mitral valve 170 but not engage location ring 120. In such an embodiment, the barbs or hooks of piercing members 115 may bind, engage with, and/or resist withdrawal from tissue proximate mitral valve 170 in a manner sufficient to keep implant 110 attached to the tissue proximate mitral valve 170. Additionally, the binding, engaging, and/or resisting withdrawal may be sufficient to decrease the surface area of mitral valve 170 as expansive force “B” and reactive reducing force “C” are applied. In such an embodiment, location ring 120 may or may not be used to facilitate placing implant 110 at a positive location proximate mitral valve 170. In some embodiments, as described, the location ring 120 may not couple with the implant 110 but may be used to facilitate positioning of the implant 110, such as by temporarily positioning the location ring 120, etc. A positive location for implant 110 may be one in which implant 110 is able to engage tissue proximate mitral valve 170 without impairing the function of mitral valve 170 and further implant 110 may be used to decrease the surface area of mitral valve 170 as expansive force “B” and reactive reducing force “C” are applied.



FIGS. 2A-2D illustrate an example of implant 110 in accordance with the present disclosure. As shown in FIG. 2A, implant 110 may be made of a metal and cut to form a mesh, a cage, or series of repeating units to allow variations in diameter. For example, implant 110 may include a tubular body of repeating squares, diamonds, hexagons, or any other shape allowing a variation in diameter of implant 110. In first structural configuration as shown in FIG. 2A, implant 110 may have the larger diameter portion initially oriented toward mitral valve 170 (the lower portion with lower diameter 220) and the smaller diameter may be oriented in the left atrium (the upper portion with upper diameter 210). The upper portion may be in free space in the left atrium and have a smaller diameter ready to be expanded in this first structural configuration.


The construction of implant 110 may include a tapered laser cut tube expanded to a predetermined diameter with wall thickness approximately 0.005 inches to approximately 0.050 inches and a strut thickness of approximately 0.010 inches to approximately 0.070 inches and an expanded diameter of approximately 1.00 inch. If the implant is tapered, the large diameter may measure about thirty five millimeters in diameter and the smaller diameter may measure about twenty five millimeters in diameter. In the first structural configuration, the lower portion (i.e. the larger diameter section) may have penetrating members 115 to engage the mitral annulus and hold implant 110 in position during annuls reduction and remain as a permanent implant.


As shown in FIG. 2B, downward force “A” may be applied to implant 110. In some embodiments, piercing members 115A-H may be driven to engage the tissue one at a time. For example, a linear force may drive the hooks or barbs of piercing member 115A into the tissue by pushing at the top of implant 110 above piercing member 115A, thus transmitting a force through to the piercing member 115A, driving it into the tissue. The delivery system or catheter applying the force may then be rotated and actuated again to engage another piercing member 115, for example adjacent piercing member 115B. Once piercing member 115B has been engaged with the tissue, this may be repeated until all piercing members 115 have been engaged with the tissue. Alternatively, in some embodiments, force “A” may be sufficient to engage multiple piercing members 115 at once, rather than engaging only a single piercing member 115 at a time. In some embodiments, all of piercing members 115 may be engaged at once.


As shown in FIG. 2C, implant 110 may be in a first structural configuration in which upper diameter 210 may be smaller than lower diameter 220. An expansive force “B” may be applied to the upper portion of implant 110. As the expansive force “B” is applied such that the upper diameter 210 is increased, the lower diameter 220 may be decreased due to a reactive reductive force “C” which is generated. A wall of the tubular body of implant 110 may act as a beam in deflection where the upper portion of implant 110, when deflected (e.g. expanded), may cause the lower portion of implant 110 to bend (e.g. contract). This may facilitate the transition from this first structural configuration to a second structural configuration. The lower diameter 220 may be proximate piercing members 115, which are engaged with the mitral valve annulus. Thus, as lower diameter 220 becomes smaller, the diameter of mitral valve 170 becomes smaller. The expansive force “B” may be applied via balloon dilation, mechanical expansion or other means to increase upper diameter 210, thus reducing lower diameter 220. This may effectively invert implant 110's dimensions about axis 200, which may be referred to as an axis of inversion or axis of reflection. In some embodiments, the diameter of implant 110 at axis 200 may remain approximately uniform in a first structural configuration, transitioning between structural configurations, and a second structural configuration. As shown in FIG. 2D, the application of expansive force “B” and thus reactive reducing force “C” may result in implant 110 with upper diameter 210 having a larger length and lower diameter 220 having a shorter length. This may in turn reduce barb-engaged mitral valve 170 to a smaller annulus cross-sectional area, lessening the mitral regurgitation. The structural configuration shown in FIG. 2B may be the second structural configuration of implant 110 in which mitral valve 170 has been reduced in annulus cross-sectional area. Additionally, this second structural configuration may be a final structural configuration that may maintain the size change of mitral valve 170.


As shown in FIGS. 3A and 3B, an alternative method for applying an expansive force to implant 310 may be the deployment of a ring 320 within implant 310. FIG. 3A illustrates implant 310 in a first structural configuration and FIG. 3B illustrates implant 310 in a second structural configuration. The ring 320 may be formed of a shape memory material, such as nitinol. The ring 320 may be collapsed into a delivery catheter for delivery therethrough to the heart and ejected into or around the implant 310. In some embodiment, one or more releasable tethers may be attached to the ring 320. The releasable tethers may be pulled on to move the ring 320 and to release the tethers from the ring 320 after the ring 320 is in the desired location.


In some embodiments, a fixed ring 320 may be utilized. Fixed ring 320 may be moved vertically to expand the upper portion to increase upper, i.e. proximal, diameter 330, thus causing the lower portion to reduce lower, i.e. distal, diameter 340 along with the engaged tissue and mitral valve. For example, upward force “D” may be applied to ring 320. However, because of the frustoconical shape of implant 310, the upward force “D” may be translated to an expansive lateral force causing an increase in upper diameter 330. Ring 320 may lock into implant 310 by an interference fit or a mechanical stop built in ring 320 or implant 310, and may maintain implant 310 in the second structural configuration. In some embodiments, the fixed ring 320 may have a smaller diameter and initially be located at or near the upper diameter 330, thus restraining the upper diameter 330 and causing and/or maintaining the first structural configuration of the implant 310 shown in FIG. 3A. The fixed ring 320 may then be moved vertically downward as oriented toward the lower diameter 340, thereby allowing the upper diameter 330 to expand and increase in size and causing the lower diameter 340 to contract and reduce in size. The fixed ring 320 may then be located at or near the lower diameter 340 to cause and/or maintain the second structural configuration of the implant 310 shown in FIG. 3B.


Alternatively, an expandable ring 320 may be used rather than a fixed ring. Expandable ring 320 may be positioned within implant 310 and may be delivered and expanded by a catheter, for example using hydraulic or mechanical force to expand ring 320. Ring 320 may be introduced into implant 310's inner diameter where ring 320 may be tilted to allow for manipulation or positioning. Alternatively, ring 320 may be placed at a defined vertical position in implant 310 and ring 320 may be expanded, for example with mechanical or hydraulic force or an extension of the radial dimension. Ring 320 may also serve as a locking mechanism for implant 310 once the second structural configuration or the final position has been reached. The expansion and/or locking of ring 320 may be reversible in nature, thus undoing the expansion of the upper portion. Ring 320 may lock into implant 310, for example by an interference fit or a mechanical stop built in ring 320 and/or implant 310.



FIGS. 4A and 4B illustrate an additional embodiment of an implant 410 for reshaping mitral valve 170. FIG. 4A illustrates implant 410 in a first structural configuration and FIG. 4B illustrates implant 410 in a second structural configuration. As shown in FIG. 4A, in some embodiments, implant 410 may include one or more support beams 420 (for example, support beams 420A and 420B). Support beams 420 may facilitate the transition of expansive force “B” to the reductive force “C.” For example, support beam 420 may operate as a beam in deflection about axis 450. Thus, as expansive force “B” is applied to the upper portion of implant 410, beams 420A and 420B may act as levers with axis 450 as the fulcrum or point of rotation, causing reductive force “C” to reduce lower diameter 440. As expansive force “B” is applied to increase upper diameter 430 and decrease lower diameter 440, implant 410 may transition from a first structural configuration shown in FIG. 4A to a second structural configuration shown in FIG. 4B. As described above, this may reduce the cross-sectional area of mitral valve 170.


Support beams 420A and 420B may be integrally formed with implant 410, for example, as a thicker portion of a wall of the tubular body of implant 410, or a specific alignment of repeating units or elements of the structure of the wall of the tubular body. Alternatively, support beams 420A and 420B may be an additional support component added to implant 410. For example, they may be glued, welded, or otherwise permanently affixed to implant 410.


As shown in FIG. 5, in addition to access to mitral valve 170 through the apex of the heart as shown by 510, access to mitral valve 170 may also be gained via the femoral artery as shown by 530, or via the femoral artery and through the aortic valve (for example, as described above with respect to delivery/removal of the location ring 120 through the aortic valve) or through the venous system and then via trans-septal puncture directly into the left atrium as shown by 520. When accessed via the femoral artery or trans-septally, a delivery catheter may measure about ninety to one hundred and fifty centimeters in length. The end of the catheter may be deflectable via deflection wires creating tension of bias to allow adjustments due to anatomical variations.


As shown in FIG. 6, vibration may be applied directly to penetrating members 115 to facilitate the barbs or hooks and/or penetrating members 115 penetrating the tissue. Low frequency vibration, ultrasonic, or Radio Frequency energy may allow a lower insertion force compared to the barb or hook's and/or penetrating members' normal penetration force. Coupling this energy source to implant 110 may allow transmission of small vibrations 620 to the tip of each barb or hook and/or penetrating member 115. Alternatively, each barb or hook and/or penetrating member 115 may have its own independent energy source allowing a variable pattern of frequency or energy around implant 110. Direct tissue contact of the energy element or a coupling to implant 110 may be used but there may be a decrease in efficiency by coupling vibration 620 thereto. The frequency of vibration 620 may be about ten to one hundred Hz (cycles per second) or may be about twenty Hz.


As shown in FIGS. 7 and 8, to aid in the engagement of the penetrating members 115, additional energy may be added to vibrate the tissue surrounding or below mitral valve 170. For example, as shown in FIG. 7, vibration pads 710A and 710B may deliver vibration 620 to the surrounding tissue near the barbs or hooks of penetrating members 115. Pads 710A and 710B may be used to vibrate the tissue near the barb insertion site. Pads 710A and 710B may be completely separate from implant 110 or may be connected to the same delivery system. A separate control for linear and radial motion of pads 710A and 710B may be provided to control the location to provide precise delivery of vibration 620.


As shown in FIG. 8, vibration pads 810A and 810B may also be located below mitral valve 170. This may still provide vibration 620 to facilitate the engagement of barbs or hooks of penetrating members 115 with tissue proximate mitral valve 170. As with the embodiment of FIG. 7, vibration pads 810A and 810B may be completely separate from implant 110 or may be connected to the same delivery system. A separate control for linear and radial motion of pads 810A and 810B may be provided to control the location to provide precise delivery of vibration 620.


Radio frequency (RF) is a rate of oscillation in the range of about three kHz to three hundred GHz, which corresponds to the frequency of radio waves, and the alternating currents, which carry radio signals. RF usually refers to electrical rather than mechanical oscillations. Below is a chart of common nomenclature for different frequency ranges. The range utilized for barb penetration may be somewhere between ELF and HF as the goal is small vibration and not heating of the tissue. Possible user range selection would allow for different tissue types and densities.












TABLE 1





Frequency
Wavelength
Designation
Abbreviation







3-30 Hz
105-104 km
Extremely low
ELF




frequency



30-300 Hz
104-103 km
Super low frequency
SLF


300-3000 Hz
103-100 km
Ultra low frequency
ULF


3-30 kHz
100-10 km
Very low frequency
VLF


30-300 kHz
10-1 km
Low frequency
LF


300 kHz-3 MHz
1 km-100 m
Medium frequency
MF


3-30 MHz
100-10 m
High frequency
HF


30-300 MHz
10-1 m
Very high frequency
VHF


300 MHz-3 GHz
1 m-10 cm
Ultra high frequency
UHF


3-30 GHz
10-1 cm
Super high
SHF




frequency



30-300 GHz
1 cm-1 mm
Extremely high
EHF




frequency



300 GHz-3000 GHz
l mm-0.1 mm
Tremendously high
THF




frequency









Vibration to enhance tissue penetration by the anchor may be delivered from a vibration source to tissue adjacent the penetration site, such as by the vibration pads discussed above. The vibration source may be embedded in the pad or other vibration interface at the distal end of an elongate control element such as a wire or tube. Alternatively, the vibration source may be located in a proximal manifold and propagate vibrational energy distally through an elongate wire or tube extending through the catheter body. The vibration source can alternatively be coupled in vibration propagating communication with either the implant frame or with each individual anchor directly, such as through the anchor driver, depending upon desired performance.



FIG. 9A depicts another embodiment of an implant 910. The implant 910 may have the same or similar features and/or functionalities as other implants described herein, and vice versa, except as otherwise described. Implant 910 comprises a frame 920, piercing members or anchors 930, and may include an expandable member 940. The frame 920 has a free or unconstrained state or, otherwise stated, nominal configuration as shown in FIG. 9A. The frame 920 may be made of a nickel titanium alloy, i.e. nitinol, or other shape memory alloy or metal. The frame 920 may be a dissimilar material as that of the expandable member 940. The frame 920 may be tubular with a wall circumferentially defining a central axis. The frame 920 may include angled segments as shown, and/or other segments, configurations, etc. The frame 920 as shown may be sinusoidally shaped, although its architecture could be of a diamond lattice or hexagonal lattice, for example. The frame 920 or portions thereof may incline radially outward with respect to the axis and/or with respect to the expandable member 940. The frame 920 may pivot about pivot joints located at or near interfaces with the expandable member 940. In some embodiments, fixed attachments are located at one or more of the joints between the frame 920 and the expandable member 940, for example at the interfaces of abutting apices of the frame 920 and the expandable member 940.


Anchors 930 may be metallic helical members. The anchors 930 may threadingly engage with the lower, i.e. distal, apices of frame 920. The anchors 930 may wind through a series of holes through holes drilled in the distal ends or distal apices of frame 920 (more clearly indicated by reference numerals 1050 in FIGS. 10, 11 and 12). The frame 920 may include a series of distal apices formed by the frame 920 proximate the distal diameter. A series of holes in each of the distal apices may be sized and spaced to receive therethrough a corresponding helical anchor 930 for rotational engagement of the distal apex by the corresponding helical anchor 930. The holes may be the same or similar to holes 1050 described for example with respect to FIG. 10. The anchors 930 may be advanced distally, and in some embodiments retracted proximally, in a rotational or corkscrew type manner. The anchors 930 may extend distally relative to the frame 920. For example, as the anchors 930 are rotated, the anchors 930 may move in the distal direction while the frame 920 is stationary. In some embodiments, the frame 920 may move distally while the anchors 930 move farther distally relative to the frame 920. Thus, the frame 920 may be located in the preferred position and the anchors 930 may then be moved distally to secure into heart tissue while the frame 920 remains axially stationary or approximately axially stationary. This allows for better accuracy with positioning of the implant 910 because there is less movement of the frame 920 while the anchors 930 are being secured to heart tissue. Further, the anchors 930 engage the frame 920, as described, for example through the series of holes in distal apices of the frame 920. This allows for a secure attachment between the anchors 930 and the frame 920 without the need for additional structure or features. The arrangement of the holes and the corresponding receiving of the anchor 930 therethrough in each apex allows for an axially secure engagement of the anchor 930 and the frame 920 while still allowing for movement of the anchor 930 by driving it with the driver 952. By axially secure it is meant that the anchor 930 will not move axially relative to the frame 920 in the absence of sufficient rotational force acting on the anchor 930, such that the anchor 930 and frame 920 are rotationally secured together after removal of the rotational force from the driver 952 thereby impeding further axial movement of the anchor 930 relative to the frame 920. The configuration of the series of holes in the frame 920 and the helical shape of the anchors 930 allows for such advantages. In FIG. 9A, the anchors 930 are shown extended distally, for example in the final stage of deployment into cardiac tissue proximate the mitral annulus. The mitral annulus is that region of transition from the left atrium to the left ventricle and proximate and above the area where the leaflets of mitral valve 170 (see FIG. 5) hinge from the left ventricle.


The implant 910 may include the expandable portion or member 940. The expandable member 940 may be stent-like. The expandable member 940 may be tubular with a wall circumferentially defining a central axis. The expandable member 940 may include angled segments as shown, and/or other segments, configurations, etc. While shown in the shape of a sinusoid, the expandable member 940 may otherwise have a diamond lattice or hexagonal lattice architecture, for example. The expandable member 940 may be a dissimilar material as that of the frame 920. The expandable member 940 may be made of metallic alloys such as stainless steel, cobalt chromium, platinum iridium and the like. The expandable member 940 may be collapsed or crimped for insertion into a delivery system and forcibly expanded, so as to undergo plastic deformation, to invert the frame 920. As shown in FIG. 9A, expandable member 940 may be integral with frame 920, for example a unified, monolithic portion or region of the frame 920. In some embodiments, the expandable member 940 is fixedly attached to frame 920 by bonding, welding, sutures, metallic bands crimped on to each structure, or otherwise connected in a fixed relationship to frame 920. In some embodiments, the expandable member 940 can have other coupling interactions with the frame 920, such as a friction fit, expansive force keeping the frame 920 secured with the expandable member 940, etc.


Implant 910 is loaded into the distal end of a delivery system (not shown), by compressing or collapsing the frame 920. Anchors 930 would be initially retracted for loading and delivery. Once positioned in a desired location proximate the mitral valve annulus, frame 920 is advanced out of the delivery system and its distal apices are abutted to the target heart tissue for anchor placement. The helical anchors are then advance, by rotation thereof, into the target cardiac tissue thereby anchoring implant 910 into the region of the mitral valve annulus. Implant 910 is then fully released from the delivery system.


After implant 910 is fully released from the delivery system, expandable member 940 is then forcibly expanded, such as by a dilatation balloon, causing frame 920 to invert. Inversion of frame 920 causes the anchor bearing distal end of frame 920 to taper or contract, causing the mitral valve annulus to reduce in size thus limiting the mitral valve regurgitation.



FIG. 9B is another embodiment of an implant 912. The implant 912 may have the same or similar features and/or functionalities as the implant 910, and vice versa, except as otherwise noted. The implant 912 comprises the expandable member 940 and piercing members or anchors 930. A frame 922 extends circumferentially about a central longitudinal axis. The frame 922 is formed to have as its free or unconstrained configuration somewhat opposite to that of the frame 920 of the implant 910. For example, as shown the lower, distal end as oriented, the end engaging anchors 930, may be smaller in diameter than the opposite upper, proximal end of the frame 922. The frame 922 may therefore incline radially inward relative to the central axis and/or relative to the expandable member 940. The frame 922 and the expandable member 940 may be formed of dissimilar materials. The frame 922 may be formed of similar materials as the frame 920 described with respect to FIG. 9A.


To perform the procedure of influencing the size of the mitral annulus, for example for treating the patient's mitral regurgitation, the expandable member 940 and the larger, proximal end of frame 922 are compressed or crimped and loaded into the distal end of a delivery system (not shown). This action also causes the distal or narrower end of frame 930 to invert. Such inversion must be restrained for loading into the delivery system.


Once positioned in the desired location proximate the heart valve annulus, such as the mitral valve annulus, the frame 922 is advanced out from the distal end of the delivery system, inverting as it is no longer constrained by the delivery system and expandable member 940 remains in the crimped configuration. The distal ends or distal apices of frame 922 are then positioned in abutting relationship to the target cardiac tissue proximate the mitral valve annulus. Helical piercing members 930 are then rotationally advanced into and in engagement with the target heart tissue in a manner very similar to the helical screw of a corkscrew advancing through a cork. The expandable member 940 is then expelled from the delivery system and forcibly expanded, for example by dilatation balloon which balloon could be an integral component of the delivery system. Expansion of the stent-like expandable member 940 causes frame 922 to revert to its nominal or free state thereby causing its distal apices and helical anchors to become narrower in diameter reducing the size of the mitral annulus and limiting the degree or extent of mitral regurgitation.



FIGS. 10, 11 and 12 are various views of another embodiment of an implant 1010. In this embodiment, the implant 1010 has a frame 1020 and an expandable member 1040 that are not formed as an integral implant, as for example in FIGS. 9A and 9B. Rather expandable member 1040 is positioned within frame 1020 proximate the proximal end thereof. Frame 1020 is made from a nickel titanium alloy, such as Nitinol, whereas expandable member 1040 is preferably made of metallic alloys such as stainless steel, cobalt chromium, platinum iridium and the like.



FIG. 10 shows frame 1020 in its free or unconstrained state with expandable member 1040 crimped and positioned within frame 1020. One or more holes 1050 are pre-drilled in the distal ends or apices of frame 1020 and oriented to accommodate the pitch of helical anchors (not shown for clarity) such as the anchors 930 of FIGS. 9A and 9B. The anchors 930 may be rotated through the holes 1050 to advance the anchors 930 distally, i.e. downward as oriented in the figure. In some embodiments, the anchors 930 may be rotated in the opposite direction through the holes 1050 to retract the anchors 930 in the opposite, proximal direction. FIG. 11 shows the frame 1020 in a constrained configuration and implant 1010 ready for loading into the distal end of a delivery system (not shown). FIG. 12 shows implant 1010 in what would be its deployed configuration. While expandable member 1040 is shown to have a diamond like lattice configuration, it is contemplated that it may also take the form of a sinusoid or a hexagonal configuration.


Delivery of implant 1010 may be conducted in similar respect to the embodiment of FIG. 9A. More specifically, implant 1010 is loaded into the distal end of a delivery system (not shown), by compressing or collapsing frame 1020 as shown in FIG. 11. Once positioned in a desired location proximate the mitral valve annulus, frame 1020 is advanced out of the delivery system and its distal apices are abutted to the target heart tissue for anchor placement. The helical anchors (not shown) are then advance, by rotation thereof, into the target cardiac tissue thereby anchoring implant 1010 into the region of the mitral valve annulus. Implant 1010 is then fully released from the delivery system.


After implant 1010 is fully released from the delivery system, expandable member 1040 is then forcibly expanded, such as by a dilatation balloon, causing frame 1020 to invert as shown in FIG. 12. Inversion of frame 1020 causes the anchor bearing distal end of frame 1020 to taper or contract, causing the mitral valve annulus to reduce in size thus limiting the mitral valve regurgitation.



FIG. 13 shows an exemplary steerable delivery system 950, including for example a catheter or catheter lumen, suitable for delivery of the various implant embodiments described herein. FIG. 13 depicts an embodiment of the implant 1010 of FIGS. 10-12, but it is understood that the delivery system 950 can be used to delivery other implants, including but limited to the implant 912 of FIG. 9B and the implant 910 of FIG. 9A, the latter of which is further shown in and described with respect to FIG. 14. For example, a similar delivery system 950 may be used for the implant 912 embodied in FIG. 9B. For brevity and since the expandable members are different between the aforementioned embodiments, the expandable members 1040 are not shown in FIG. 13.


The delivery system 950 may include a tube or tube-like structure having one or more lumens extending therethrough. For instance, the delivery system 950 may include an elongated tube or delivery catheter having one or more openings, i.e. lumens, extending therethrough and configured to receive therein, or having therein, corresponding features of the delivery system 950, including but not limited to the guide wire 160, the catheter 140, one or more of the drivers 952, and the intracardiac echo catheter 960. In some embodiments, the delivery system 950 includes a delivery catheter having a lumen to guide the delivery catheter over the guide wire, another lumen or lumens that include(s) the rotatable drivers 952, the implant 912 in a constrained delivery configuration located at a distal end of the delivery catheter, and a sheath covering the distal end of the catheter. Delivery system 950 is advanced transfemorally, either through the femoral vein and transeptally to the left atrium or through the femoral artery up through the aortic arch and then passed the aortic and mitral valves into the left atrium. Once positioned above mitral annulus and proximate the target heart tissue, the implant is partially released, releasing the frame portion 920, 1020. Frame 920, 1020 is now unconstrained and able to return to its nominal or free state as shown in FIG. 13.


Helical piercing members 930 are then rotationally advanced into the target cardiac tissue, anchoring the implant to the interior heart wall above the mitral annulus. The implant and expandable member 940, 1040 is then released from delivery system 950. At such time, the stent like member 940, 1040 is forcibly expanded causing the frame 920, 1020 to invert. The distal end of apices and helical anchors 930 are then cinched inwardly reducing the diameter of the distal end of frame 920, 1020 causing a corresponding reduction in the size of the mitral annulus. This reduction in size of the mitral annulus, allows the mitral valve leaflets to better, if not completely, coapt reducing the severity of the patient's mitral regurgitation.


In a further embodiment of the present invention, an intracardiac echo catheter 960 is incorporated in delivery system 950. Catheter 960 could be included in a lumen of delivery system 950, either internally as shown, or alongside implant delivery system 950. By rotating catheter 960 within the left atrium and proximate the mitral valve annulus, the relative position of the implant with respect to the mitral valve leaflets can be determined. This allows for accurate positioning of helical anchors 930 into the target heart tissue proximate the mitral annulus without piercing the mitral valve leaflets.



FIG. 14 depicts the steerable delivery system 950 being used to deliver the implant 910 of FIG. 9A. The description of the delivery system 950 above with respect to FIG. 13 applies to use of the system 950 with the implant 910, and vice versa, except as otherwise noted. As shown in FIG. 14, the implant 910 thus includes the frame 920 and expandable member 940, shown as integral with the frame 920. In some embodiments, the implant 910 may only include the frame 920. The delivery system 950 may or may not include the intracardiac echo catheter 960, as described above.


As shown in FIG. 14, a plurality of rotational drivers 952 extends out through a distal opening of a lumen of the delivery catheter and/or sheath of the delivery system 950. Each driver 952 may extend through a corresponding lumen of the delivery system 950. In some embodiments, more than one or all of the drivers 952 may extend through the same lumen of the delivery system 950. A guide wire, such as the guide wire 160, may also be incorporated into the delivery system 950, and may extend through a lumen of the delivery system 950.


The drivers 952, only some of which are labelled for clarity, are each engaged with a corresponding rotational anchor 930. The drivers 952 may be pre-engaged with the anchors 930 within the delivery catheter of the delivery system 950 before insertion of the distal end of the delivery system 950 into the atrium. The drivers 962 may be mechanically engaged with the anchors 930 in a variety of suitable approaches. For example, the drivers 962 may have a clevis type fitting as shown configured to surround the proximal end of the anchors 930. The drivers 952 may extend over, on, under, etc. the proximal ends of the anchors 930 and then be rotated to transmit rotation to the anchors 930. In some embodiments, the anchors 930 may have recesses or other tool-receiving portions engaged by the drivers 952 such that rotation of the drivers 952 is transmitted to the anchors 930. In some embodiments, the drivers 952 may include socket type fittings that surround the anchors 930. In some embodiments, the anchors 930 may have internally-threaded blind holes through which corresponding externally-threaded members of the drivers 952 are received. These are merely some examples of how the drivers 952 may be engaged with the anchors 930, and other suitable approaches may be implemented. With the implant 910 in position for anchoring to the annulus, a proximal end of the drivers 962 may be manipulated by the user, for example rotated by the surgeon, to rotate the anchors 930 and thereby advance the anchors 930 into heart tissue, as described herein, to secure the implant 910 with the heart tissue. Each driver 952 may be actuated simultaneously, some may be actuated simultaneously, or they may be actuated sequentially. The anchors 930 may extend distally relative to the frame, as described herein.



FIGS. 15A-15D show sequential views of an embodiment of a transcatheter delivery system for delivering the implant 910 showing an embodiment of a method for the delivery, positioning and anchoring of the implant 910 for resizing the native valve annulus. The various delivery systems as described herein may be used. As shown, the delivery system may include the sheath 150, the catheter 140 and the guide wire 160. The sheath 150, the catheter 140, the guide wire 160 and the implant 910 are configured for transcatheter delivery of the implant 910 to the heart. The implant 910 may be delivered by the delivery system percutaneously by catheter through an opening in the femoral vein. The implant 910 may be advanced through the femoral vein into the vena cava and into the right atrium. The distal ends of the sheath 150, catheter 140, and guide wire 160 are configured to extend through the opening in the femoral vein, through the femoral vein and into the right atrium of the heart, and through the septum of the heart into the left atrium.


As shown in FIG. 15A, the guidewire 160 may be advanced through the septum separating the upper chambers of the heart and the sheath 150 and catheter 140 may be advanced to that position along the guide wire 140. The distal end of the catheter 140 is advanced to a position above the heart valve annulus, for example, the mitral valve annulus, as shown in FIG. 15B. FIG. 15C shows the implant 910 expelled from the distal end of the sheath 150 above and proximate to the mitral valve annulus. In some embodiments, a series of images may be taken, for example with an intracardiac echo catheter, to properly position the anchors 930 for insertion into the mitral valve annulus tissue. As shown in FIGS. 15C and 15D, the anchors 930 may be rotationally engaged by rotational drivers of the delivery system, such as the drivers 952 described herein, for rotation and distal advancement of the anchors 930 into the heart valve annulus. In some embodiments, a circumferential image may be captured to confirm that all anchors 930 are appropriately placed and anchored in the mitral valve annulus tissue above the mitral valve leaflets. If one or more anchors 930 are not positioned or anchored properly, the drivers 952 may reverse the direction of rotation to rotationally retract the anchors in the proximal direction. The anchors 930 can then be repositioned and re-anchored prior to removal of the drivers 952.


Though a particular path of transcatheter delivery is described with respect to FIGS. 15A-15D, a variety of other delivery paths and approaches may be employed, including but not limited to the paths shown and described with respect to FIGS. 1A-1F, trans-apical delivery, etc. In addition, any of the features and/or functionalities of the delivery system and associated methods described with respect to FIGS. 1A-1F may be incorporated with respect to the delivery system and methods described with respect to FIGS. 15A-15D, and vice versa. Therefore, for example, with regard to the delivery system and methods described with respect to FIGS. 15A-15D, the implant 910 may “invert” as described herein, an expandable or fixed ring 320 may be utilized as described, the location ring 120 may be inserted below the valve, etc.


This disclosure encompasses all changes, substitutions, variations, alterations, and modifications to the example embodiments herein that a person having ordinary skill in the art would comprehend. Similarly, where appropriate, the appended claims encompass all changes, substitutions, variations, alterations, and modifications to the example embodiments herein that a person having ordinary skill in the art would comprehend. Moreover, reference in the appended claims to an apparatus or system or a component of an apparatus or system being adapted to, arranged to, capable of, configured to, enabled to, operable to, or operative to perform a particular function encompasses that apparatus, system, component, whether or not it or that particular function is activated, turned on, or unlocked, as long as that apparatus, system, or component is so adapted, arranged, capable, configured, enabled, operable, or operative. For example, various embodiments may perform all, some, or none of the steps described above. Various embodiments may also perform the functions described in various orders.


Although the present disclosure has been described above in connection with several embodiments; changes, substitutions, variations, alterations, transformations, and modifications may be suggested to one skilled in the art, and it is intended that the present disclosure encompass such changes, substitutions, variations, alterations, transformations, and modifications as fall within the spirit and scope of the appended claims.

Claims
  • 1. A method of adjusting annular cardiac tissue, said method comprising: advancing an implantable device to cardiac tissue, said implantable device including a first expandable portion and a second expandable portion, the first expandable portion comprising a plurality of angled segments extending circumferentially around a central axis, wherein the first expandable portion and the second expandable portion are advanced to cardiac tissue in a collapsed configuration;expanding the first expandable portion radially outwardly from the central axis thereof at the cardiac tissue;expanding the second expandable portion separately from the first expandable portion at the cardiac tissue;engaging a portion of the implantable device with the annular cardiac tissue; androtating a component of the implantable device with respect to the annular cardiac tissue.
  • 2. The method of claim 1, further comprising axially moving a tissue-securing element of the implantable device with respect to the first expandable portion of the implantable device.
  • 3. The method of claim 2, further comprising axially advancing the tissue-securing element into tissue.
  • 4. The method of claim 2, further comprising rotating the tissue-securing element relative to tissue.
  • 5. The method of claim 2, further comprising axially securing the tissue-securing element with respect to the first expandable portion.
  • 6. The method of claim 1, further comprising rotating a tissue-securing element of the device relative to tissue.
  • 7. The method of claim 6, further comprising axially securing the tissue-securing element with respect to the first expandable portion.
  • 8. The method of claim 1, further comprising axially securing a tissue-securing element of the device with respect to the first expandable portion.
  • 9. The method of claim 1, wherein said method further comprises axially securing a tissue-securing element with respect to the annular cardiac tissue.
  • 10. The method of claim 9, further comprising rotating the tissue-securing element relative to tissue.
  • 11. A method of adjusting cardiac tissue, said method comprising: advancing an implantable device to cardiac tissue, said implantable device including a first expandable portion comprising a plurality of interconnected elements, and a second expandable portion expandable independently of the first expandable portion;engaging a portion of the implantable device with cardiac tissue; androtating a component of the implantable device threadedly coupled to the first expandable portion with respect to the cardiac tissue.
  • 12. The method of claim 11, wherein the implantable device comprises a tissue-securing element, said method further comprising axially engaging the tissue-securing element with the cardiac tissue.
  • 13. The method of claim 11, further comprising rotating a tissue-securing element of the implantable device relative to tissue.
  • 14. The method of claim 11, wherein the first expandable portion further comprises a tissue-securing element engageable with the cardiac tissue.
  • 15. The method of claim 14, further comprising axially moving the tissue-securing element with respect to the cardiac tissue.
  • 16. A method of adjusting cardiac tissue, said method comprising: delivering an implantable device into a heart using a delivery system, the implantable device including a first expandable portion comprising a plurality of interconnected angled elements extending circumferentially around a central axis in a delivery configuration and in a deployed configuration, and a second expandable portion, the plurality of interconnected angled elements of the first expandable portion expanding radially away from the central axis and independently of the second expandable portion upon deploying the implantable device; androtating at least a component of the delivery system to adjust an associated component of the implantable device with respect to the heart to adjust the configuration of cardiac tissue within the heart.
  • 17. The method of claim 16, further comprising delivering the implantable device through the left atrium.
  • 18. The method of claim 17, further comprising delivering the implantable device transeptally into the left atrium.
  • 19. The method of claim 16, further comprising moving the implantable device with respect to the heart to adjust the configuration of the cardiac tissue.
  • 20. The method of claim 16, further comprising: engaging a tissue-engaging component of the implantable device with cardiac tissue; androtating the tissue-engaging component of the device with respect to the annular cardiac tissue.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of Ser. No. 17/081,128, filed Oct. 27, 2020, which is a continuation of Ser. No. 15/423,374, filed Feb. 2, 2017, which claims the benefit of priority to U.S. Provisional Application No. 62/291,347, filed on Feb. 4, 2016, and which is a Continuation-in-Part Applications of U.S. application Ser. No. 14/427,909, filed on Mar. 12, 2015, which is a U.S. National Phase Application of PCT International Application No. PCT/US2013/059751, filed on Sep. 13, 2013, designating the United States of America and published in the English language, which is an International Application of and claims the benefit of priority to U.S. Provisional Application No. 61/700,989, filed on Sep. 14, 2012. Each of the above-referenced applications are hereby expressly incorporated by reference herein in their entireties for all purposes and form a part of this specification. Any and all priority claims identified in the Application Data Sheet, or any correction thereto, are hereby incorporated by reference under 37 C.F.R. § 1.57.

US Referenced Citations (435)
Number Name Date Kind
3143742 Cromie Aug 1964 A
4042979 Angell Aug 1977 A
4290151 Massana Sep 1981 A
4602911 Ahmadi et al. Jul 1986 A
4820299 Philippe et al. Apr 1989 A
5064431 Gilbertson et al. Nov 1991 A
5254127 Wholey et al. Oct 1993 A
5370685 Stevens Dec 1994 A
5674279 Wright et al. Oct 1997 A
5674280 Davidson et al. Oct 1997 A
5769816 Barbut et al. Jun 1998 A
5772590 Webster, Jr. Jun 1998 A
5810882 Bolduc et al. Sep 1998 A
5824066 Gross Oct 1998 A
5968053 Revelas Oct 1999 A
5984959 Robertson et al. Nov 1999 A
6001127 Schoon et al. Dec 1999 A
6059731 Seward et al. May 2000 A
6074418 Buchanan et al. Jun 2000 A
6176877 Buchanan et al. Jan 2001 B1
6210432 Solem et al. Apr 2001 B1
6254642 Taylor Jul 2001 B1
6355030 Aldrich et al. Mar 2002 B1
6402780 Williamson, IV et al. Jun 2002 B2
6582460 Cryer Jun 2003 B1
6629534 St. Goar et al. Oct 2003 B1
6652537 Mercereau et al. Nov 2003 B2
6676692 Rabkin et al. Jan 2004 B2
6695878 McGuckin, Jr. et al. Feb 2004 B2
6702826 Liddicoat Mar 2004 B2
6726716 Marquez Apr 2004 B2
6730121 Ortiz et al. May 2004 B2
6743239 Kuehn et al. Jun 2004 B1
6776791 Stallings et al. Aug 2004 B1
6786925 Schoon et al. Sep 2004 B1
6790231 Liddicoat et al. Sep 2004 B2
6805710 Bolling et al. Oct 2004 B2
6824562 Mathis et al. Nov 2004 B2
6875231 Anduiza et al. Apr 2005 B2
6913608 Liddicoat et al. Jul 2005 B2
6942641 Seddon Sep 2005 B2
6942694 Liddicoat et al. Sep 2005 B2
6951571 Srivastava Oct 2005 B1
6964684 Ortiz et al. Nov 2005 B2
6974476 McGuckin, Jr. et al. Dec 2005 B2
6986775 Morales et al. Jan 2006 B2
7007698 Thornton Mar 2006 B2
7041120 Li et al. May 2006 B2
7063722 Marquez Jun 2006 B2
7081131 Thornton Jul 2006 B2
7087064 Hyde Aug 2006 B1
7112219 Vidlund et al. Sep 2006 B2
7160322 Gabbay Jan 2007 B2
7166127 Spence et al. Jan 2007 B2
7192442 Solem et al. Mar 2007 B2
7247134 Vidlund et al. Jul 2007 B2
7297150 Cartledge et al. Nov 2007 B2
7323004 Parihar Jan 2008 B2
7329278 Seguin et al. Feb 2008 B2
7329280 Bolling et al. Feb 2008 B2
7335213 Hyde et al. Feb 2008 B1
7357815 Shaoulian et al. Apr 2008 B2
7361190 Shaoulian et al. Apr 2008 B2
7381218 Schreck Jun 2008 B2
7404824 Webler et al. Jul 2008 B1
7455690 Cartledge et al. Nov 2008 B2
7482936 Bolling Jan 2009 B2
7485142 Milo Feb 2009 B2
7507252 Lashinski et al. Mar 2009 B2
7527646 Rahdert et al. May 2009 B2
7534204 Starksen et al. May 2009 B2
7556647 Drews et al. Jul 2009 B2
7611534 Kapadia et al. Nov 2009 B2
7637946 Solem et al. Dec 2009 B2
7655040 Douk et al. Feb 2010 B2
7674222 Nikolic et al. Mar 2010 B2
7691144 Chang et al. Apr 2010 B2
7695510 Bloom et al. Apr 2010 B2
7722667 Buchanan May 2010 B1
7731649 Ferrazzi Jun 2010 B2
7740638 Hyde Jun 2010 B2
D627245 Corn et al. Nov 2010 S
7850709 Cummins et al. Dec 2010 B2
7860555 Saadat Dec 2010 B2
7887582 Mathis et al. Feb 2011 B2
7896913 Damm et al. Mar 2011 B2
7914576 Navia et al. Mar 2011 B2
7914577 Cox Mar 2011 B2
7927371 Navia et al. Apr 2011 B2
7935145 Alfieri et al. May 2011 B2
7959673 Carpentier et al. Jun 2011 B2
7972378 Tabor et al. Jul 2011 B2
7988725 Gross et al. Aug 2011 B2
7993395 Vanerman et al. Aug 2011 B2
8012202 Alameddine Sep 2011 B2
8016877 Seguin et al. Sep 2011 B2
8052751 Aklog et al. Nov 2011 B2
8128641 Wardle Mar 2012 B2
8142494 Rahdert et al. Mar 2012 B2
8142496 Berreklouw Mar 2012 B2
8157853 Laske et al. Apr 2012 B2
8163013 Machold et al. Apr 2012 B2
8182528 Salahieh et al. May 2012 B2
8187207 Machold et al. May 2012 B2
8187324 Webler et al. May 2012 B2
8211171 Kim et al. Jul 2012 B2
8226707 White Jul 2012 B2
8277502 Miller et al. Oct 2012 B2
8287555 Starksen et al. Oct 2012 B2
8287591 Keidar et al. Oct 2012 B2
8333777 Schaller et al. Dec 2012 B2
8349002 Milo Jan 2013 B2
8357195 Kuehn Jan 2013 B2
8366766 Berreklouw Feb 2013 B2
8382653 Dubi et al. Feb 2013 B2
8430926 Kirson Apr 2013 B2
8449604 Moaddeb et al. May 2013 B2
8454683 Rafiee et al. Jun 2013 B2
8480733 Navia et al. Jul 2013 B2
8512403 Navia et al. Aug 2013 B2
8551161 Dolan Oct 2013 B2
8551162 Fogarty et al. Oct 2013 B2
8560009 Etemad Oct 2013 B2
8579964 Lane et al. Nov 2013 B2
8603159 Seguin et al. Dec 2013 B2
8608797 Gross et al. Dec 2013 B2
8668713 Horan et al. Mar 2014 B2
8673001 Cartledge et al. Mar 2014 B2
8685080 White Apr 2014 B2
8690858 Machold et al. Apr 2014 B2
8690939 Miller et al. Apr 2014 B2
8715342 Zipory et al. May 2014 B2
8721681 Ruff et al. May 2014 B2
8721718 Kassab May 2014 B2
8758372 Cartledge et al. Jun 2014 B2
8778021 Cartledge Jul 2014 B2
8784482 Rahdert et al. Jul 2014 B2
8808371 Cartledge Aug 2014 B2
8858622 Machold et al. Oct 2014 B2
8864823 Cartledge et al. Oct 2014 B2
8882830 Cartledge et al. Nov 2014 B2
8906046 Anderson Dec 2014 B2
8926696 Cabiri et al. Jan 2015 B2
8940042 Miller et al. Jan 2015 B2
8945210 Cartledge et al. Feb 2015 B2
8956407 Macoviak et al. Feb 2015 B2
8979923 Spence et al. Mar 2015 B2
8979925 Chang et al. Mar 2015 B2
8992604 Gross et al. Mar 2015 B2
8998979 Seguin et al. Apr 2015 B2
9005272 White Apr 2015 B2
9011520 Miller et al. Apr 2015 B2
9023065 Bolduc et al. May 2015 B2
9040092 Edelman et al. May 2015 B2
9044221 Zentgraf et al. Jun 2015 B2
9084677 Cartledge Jul 2015 B2
9095277 House et al. Aug 2015 B2
9101338 Hindrichs et al. Aug 2015 B2
9107749 Bobo et al. Aug 2015 B2
9107750 Cartledge et al. Aug 2015 B2
9119718 Keranen Sep 2015 B2
9138315 Straubinger et al. Sep 2015 B2
9180005 Lashinski et al. Nov 2015 B1
9192471 Bolling Nov 2015 B2
9192472 Gross et al. Nov 2015 B2
9198755 Shaolian et al. Dec 2015 B2
9204956 Chanduszko et al. Dec 2015 B2
9204964 Dahlgren et al. Dec 2015 B2
9265608 Miller et al. Feb 2016 B2
9301756 Wardle Apr 2016 B2
9301860 White Apr 2016 B2
9314336 Furnish et al. Apr 2016 B2
9326859 Cartledge et al. May 2016 B2
9339379 Quadri et al. May 2016 B2
9351830 Gross et al. May 2016 B2
RE46126 Kirson Aug 2016 E
RE46127 Kirson Aug 2016 E
9421099 Dolan Aug 2016 B2
9427215 Cartledge et al. Aug 2016 B2
9439763 Geist et al. Sep 2016 B2
9474606 Zipory et al. Oct 2016 B2
9492276 Lee et al. Nov 2016 B2
9504572 Mauch et al. Nov 2016 B2
9566178 Cartledge et al. Feb 2017 B2
9585747 Quadri et al. Mar 2017 B2
9592122 Zipory et al. Mar 2017 B2
9597184 Machold et al. Mar 2017 B2
9610156 Lashinski Apr 2017 B2
9616197 Serina et al. Apr 2017 B2
9713530 Cabiri et al. Jul 2017 B2
9730790 Quadri et al. Aug 2017 B2
9744038 Dahlgren et al. Aug 2017 B2
9775709 Miller et al. Oct 2017 B2
9788941 Hacohen Oct 2017 B2
9801714 White Oct 2017 B2
9827093 Cartledge et al. Nov 2017 B2
9848983 Lashinski et al. Dec 2017 B2
9861475 Machold et al. Jan 2018 B2
9872769 Gross et al. Jan 2018 B2
9883943 Gross et al. Feb 2018 B2
9974653 Gross et al. May 2018 B2
20010044637 Jacobs et al. Nov 2001 A1
20020002401 McGuckin, Jr. et al. Jan 2002 A1
20020042621 Liddicoat et al. Apr 2002 A1
20020072710 Stewart et al. Jun 2002 A1
20020151961 Lashinski et al. Oct 2002 A1
20020161377 Rabkin Oct 2002 A1
20020173841 Ortiz et al. Nov 2002 A1
20020183837 Streeter et al. Dec 2002 A1
20030040793 Marquez Feb 2003 A1
20030050693 Quijano et al. Mar 2003 A1
20030083742 Spence et al. May 2003 A1
20030093148 Bolling et al. May 2003 A1
20030158570 Ferrazzi Aug 2003 A1
20030199974 Lee et al. Oct 2003 A1
20030199975 Gabbay Oct 2003 A1
20030199987 Berg et al. Oct 2003 A1
20030212453 Mathis et al. Nov 2003 A1
20030225420 Wardle Dec 2003 A1
20030233142 Morales et al. Dec 2003 A1
20040010275 Jacobs et al. Jan 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040067544 Vogel et al. Apr 2004 A1
20040092965 Parihar May 2004 A1
20040122516 Fogarty et al. Jun 2004 A1
20040127982 Machold et al. Jul 2004 A1
20040133274 Webler et al. Jul 2004 A1
20040148019 Vidlund et al. Jul 2004 A1
20040148020 Vidlund et al. Jul 2004 A1
20040148021 Cartledge et al. Jul 2004 A1
20040167620 Ortiz et al. Aug 2004 A1
20040172063 Li et al. Sep 2004 A1
20040186565 Schreck Sep 2004 A1
20040186566 Hindrichs et al. Sep 2004 A1
20040193191 Starksen et al. Sep 2004 A1
20040193261 Berreklouw Sep 2004 A1
20040236419 Milo Nov 2004 A1
20040243104 Seddon Dec 2004 A1
20040243227 Starksen et al. Dec 2004 A1
20040243230 Navia et al. Dec 2004 A1
20040249400 Vargas et al. Dec 2004 A1
20040249453 Cartledge et al. Dec 2004 A1
20040260394 Douk et al. Dec 2004 A1
20050004665 Aklog Jan 2005 A1
20050004668 Aklog et al. Jan 2005 A1
20050038508 Gabbay Feb 2005 A1
20050049692 Numamoto et al. Mar 2005 A1
20050075713 Bianucci et al. Apr 2005 A1
20050080454 Drews et al. Apr 2005 A1
20050119734 Spence et al. Jun 2005 A1
20050131533 Alfieri et al. Jun 2005 A1
20050137701 Salahieh et al. Jun 2005 A1
20050177180 Kaganov et al. Aug 2005 A1
20050182290 Lau et al. Aug 2005 A1
20050182486 Gabbay Aug 2005 A1
20050192629 Saadat et al. Sep 2005 A1
20050197696 Gomez Duran Sep 2005 A1
20050234508 Cummins et al. Oct 2005 A1
20050250986 Rothe et al. Nov 2005 A1
20050267560 Bates Dec 2005 A1
20050267572 Schoon et al. Dec 2005 A1
20050288776 Shaoulian et al. Dec 2005 A1
20050288783 Shaoulian et al. Dec 2005 A1
20060015178 Moaddeb et al. Jan 2006 A1
20060020332 Lashinski et al. Jan 2006 A1
20060025854 Lashinski et al. Feb 2006 A1
20060025855 Lashinski et al. Feb 2006 A1
20060025858 Alameddine Feb 2006 A1
20060069429 Spence et al. Mar 2006 A1
20060100699 Vidlund et al. May 2006 A1
20060106305 Lau May 2006 A1
20060106456 Machold et al. May 2006 A9
20060129235 Seguin et al. Jun 2006 A1
20060149349 Garbe Jul 2006 A1
20060149368 Spence Jul 2006 A1
20060178733 Pinchuk et al. Aug 2006 A1
20060184240 Jimenez et al. Aug 2006 A1
20060184241 Marquez Aug 2006 A1
20060195012 Mortier et al. Aug 2006 A1
20060206203 Yang et al. Sep 2006 A1
20060229708 Powell et al. Oct 2006 A1
20060241746 Shaoulian et al. Oct 2006 A1
20060241747 Shaoulian et al. Oct 2006 A1
20060241748 Lee et al. Oct 2006 A1
20060282161 Huynh et al. Dec 2006 A1
20060282162 Nguyen et al. Dec 2006 A1
20070005129 Damm et al. Jan 2007 A1
20070016287 Cartledge et al. Jan 2007 A1
20070016288 Gurskis et al. Jan 2007 A1
20070027533 Douk Feb 2007 A1
20070027536 Mihaljevic et al. Feb 2007 A1
20070049942 Hindrichs et al. Mar 2007 A1
20070050019 Hyde Mar 2007 A1
20070055368 Rhee et al. Mar 2007 A1
20070083259 Bloom et al. Apr 2007 A1
20070093890 Eliasen et al. Apr 2007 A1
20070112423 Chu May 2007 A1
20070112425 Schaller et al. May 2007 A1
20070142907 Moaddeb et al. Jun 2007 A1
20070156233 Kapadia et al. Jul 2007 A1
20070161846 Nikolic et al. Jul 2007 A1
20070239272 Navia et al. Oct 2007 A1
20070244553 Rafiee et al. Oct 2007 A1
20070244554 Rafiee et al. Oct 2007 A1
20070244555 Rafiee et al. Oct 2007 A1
20070244556 Rafiee et al. Oct 2007 A1
20070250161 Dolan Oct 2007 A1
20070265701 Gurskis et al. Nov 2007 A1
20070276478 Marmureanu et al. Nov 2007 A1
20070282436 Pinchuk Dec 2007 A1
20070293942 Mirzaee Dec 2007 A1
20070299543 Cartledge et al. Dec 2007 A1
20080027483 Cartledge et al. Jan 2008 A1
20080067713 Bordener Mar 2008 A1
20080071364 Kaye et al. Mar 2008 A1
20080077235 Kirson Mar 2008 A1
20080177380 Starksen et al. Jul 2008 A1
20080255661 Straubinger et al. Oct 2008 A1
20080262609 Gross et al. Oct 2008 A1
20080288060 Kaye et al. Nov 2008 A1
20090082857 Lashinski et al. Mar 2009 A1
20090087414 Edelman et al. Apr 2009 A1
20090149872 Gross et al. Jun 2009 A1
20090177276 Carpentier et al. Jul 2009 A1
20090182419 Bolling Jul 2009 A1
20090198316 Laske et al. Aug 2009 A1
20090259304 O'Beirne Oct 2009 A1
20090264996 Vanerman et al. Oct 2009 A1
20090276040 Rowe et al. Nov 2009 A1
20090287299 Tabor et al. Nov 2009 A1
20090287304 Dahlgren et al. Nov 2009 A1
20090306622 Machold et al. Dec 2009 A1
20100004740 Seguin et al. Jan 2010 A1
20100049315 Kirson Feb 2010 A1
20100087855 Leung et al. Apr 2010 A1
20100100174 Gurskis Apr 2010 A1
20100121433 Bolling et al. May 2010 A1
20100152838 Kang et al. Jun 2010 A1
20100152840 Seguin et al. Jun 2010 A1
20100152845 Bloom et al. Jun 2010 A1
20100185229 Horan et al. Jul 2010 A1
20100249920 Bolling et al. Sep 2010 A1
20100280604 Zipory et al. Nov 2010 A1
20100298929 Thornton et al. Nov 2010 A1
20110022166 Dahlgren et al. Jan 2011 A1
20110060407 Ketai et al. Mar 2011 A1
20110066224 White Mar 2011 A1
20110066236 Khalapyan Mar 2011 A1
20110106245 Miller et al. May 2011 A1
20110106247 Miller et al. May 2011 A1
20110166649 Gross et al. Jul 2011 A1
20110172760 Anderson Jul 2011 A1
20110190879 Bobo et al. Aug 2011 A1
20110202127 Mauch et al. Aug 2011 A1
20110219603 White Sep 2011 A1
20110224785 Hacohen Sep 2011 A1
20110230956 White Sep 2011 A1
20110230961 Langer et al. Sep 2011 A1
20110288632 White Nov 2011 A1
20110319989 Lane et al. Dec 2011 A1
20120022640 Gross et al. Jan 2012 A1
20120027116 Etemad Feb 2012 A1
20120053680 Bolling et al. Mar 2012 A1
20120109288 Bolling May 2012 A1
20120109289 Bolling May 2012 A1
20120136436 Cabiri May 2012 A1
20120197388 Khairkhahan et al. Aug 2012 A1
20120203330 Cartledge et al. Aug 2012 A1
20120209379 Shaolian et al. Aug 2012 A1
20120215303 Quadri et al. Aug 2012 A1
20120283757 Miller et al. Nov 2012 A1
20120308610 Edelman et al. Dec 2012 A1
20130006295 Chanduszko et al. Jan 2013 A1
20130030523 Padala et al. Jan 2013 A1
20130046373 Cartledge et al. Feb 2013 A1
20130123910 Cartledge et al. May 2013 A1
20130123913 Kuehn May 2013 A1
20130138207 Quadri et al. May 2013 A1
20130144380 Quadri et al. Jun 2013 A1
20130177600 Edelman et al. Jul 2013 A1
20130226289 Shaolian et al. Aug 2013 A1
20130289710 Leedle Oct 2013 A1
20130289719 Dobrilovic Oct 2013 A1
20130296999 Burriesci et al. Nov 2013 A1
20130325118 Cartledge Dec 2013 A1
20140018913 Cartledge et al. Jan 2014 A1
20140039612 Dolan Feb 2014 A1
20140142695 Gross et al. May 2014 A1
20140163690 White Jun 2014 A1
20140222136 Geist et al. Aug 2014 A1
20140277427 Ratz et al. Sep 2014 A1
20140277563 White Sep 2014 A1
20140296962 Cartledge et al. Oct 2014 A1
20140309731 Quadri et al. Oct 2014 A1
20140336756 Lee et al. Nov 2014 A1
20150081014 Gross et al. Mar 2015 A1
20150112432 Reich et al. Apr 2015 A1
20150127096 Rowe et al. May 2015 A1
20150142105 Bolling et al. May 2015 A1
20150148896 Karapetian et al. May 2015 A1
20150157459 Macoviak et al. Jun 2015 A1
20150250461 Berreklouw Sep 2015 A1
20160008130 Hasin Jan 2016 A1
20160015513 Lashinski et al. Jan 2016 A1
20160015514 Lashinski et al. Jan 2016 A1
20160015515 Lashinski et al. Jan 2016 A1
20160038285 Glenn et al. Feb 2016 A1
20160095704 Whitman Apr 2016 A1
20160120645 Alon May 2016 A1
20160128829 Oba et al. May 2016 A1
20160235526 Lashinski et al. Aug 2016 A1
20160256276 Yaron Sep 2016 A1
20160317304 Spence et al. Nov 2016 A1
20160324638 Dolan Nov 2016 A1
20160346084 Taylor et al. Dec 2016 A1
20160361168 Gross et al. Dec 2016 A1
20160361169 Gross et al. Dec 2016 A1
20170000609 Gross et al. Jan 2017 A1
20170035562 Quadri et al. Feb 2017 A1
20170035564 Ryan et al. Feb 2017 A1
20170049570 O'Beimne et al. Feb 2017 A1
20170086974 Lashinski et al. Mar 2017 A1
20170143488 Lashinski et al. May 2017 A1
20170156860 Lashinski et al. Jun 2017 A1
20170209253 Lashinski et al. Jul 2017 A1
20170231759 Geist et al. Aug 2017 A1
20170348098 Rowe et al. Dec 2017 A1
20170360549 Lashinski et al. Dec 2017 A1
20170367825 Cabiri et al. Dec 2017 A1
20180014934 Miller et al. Jan 2018 A1
20180028311 Hacohen Feb 2018 A1
20180085217 Lashinski et al. Mar 2018 A1
20180228610 Lashinski et al. Aug 2018 A1
20180263776 Gross et al. Sep 2018 A1
20180263777 Gross et al. Sep 2018 A1
Foreign Referenced Citations (65)
Number Date Country
0624080 Dec 2001 EP
1872743 Jan 2008 EP
2047824 May 2012 EP
2656816 Oct 2013 EP
2008538937 Nov 2008 JP
2010284536 Dec 2010 JP
9009153 Aug 1990 WO
9315690 Aug 1993 WO
9712565 Apr 1997 WO
9720524 Jun 1997 WO
9824386 Jun 1998 WO
9929269 Jun 1999 WO
9949816 Oct 1999 WO
0007521 Feb 2000 WO
0018333 Apr 2000 WO
0044311 Aug 2000 WO
0062715 Oct 2000 WO
0189440 Nov 2001 WO
02034121 May 2002 WO
02094132 Nov 2002 WO
03017874 Mar 2003 WO
03053289 Jul 2003 WO
03080150 Oct 2003 WO
03015670 Dec 2003 WO
03105730 Dec 2003 WO
04014282 Feb 2004 WO
04019816 Mar 2004 WO
04019826 Mar 2004 WO
04030569 Apr 2004 WO
04031717 Apr 2004 WO
04032717 Apr 2004 WO
04082538 Sep 2004 WO
04103223 Dec 2004 WO
04112657 Dec 2004 WO
05002424 Jan 2005 WO
05007037 Jan 2005 WO
05046488 May 2005 WO
05087139 Sep 2005 WO
06011275 Feb 2006 WO
06052687 May 2006 WO
06086135 Aug 2006 WO
06086434 Aug 2006 WO
06105084 Oct 2006 WO
06116129 Nov 2006 WO
06116357 Nov 2006 WO
07021834 Feb 2007 WO
07103562 Sep 2007 WO
07136783 Nov 2007 WO
0815257 Feb 2008 WO
08068756 Jun 2008 WO
08088716 Jul 2008 WO
09120764 Oct 2009 WO
09126629 Oct 2009 WO
09140268 Nov 2009 WO
10011699 Jan 2010 WO
10048151 Apr 2010 WO
12027116 Mar 2012 WO
12167095 Dec 2012 WO
13088327 Jun 2013 WO
14043527 Mar 2014 WO
2014043527 Mar 2014 WO
2014210263 Dec 2014 WO
2015057407 Apr 2015 WO
1577599 May 2015 WO
2015148241 Oct 2015 WO
Non-Patent Literature Citations (34)
Entry
B.Braun Medical Inc., “Pulmonary Embolism:IVC Filters.” Retrieved from the Internet: http://www.bbraunusa.com/pe/be05a.html, 2004, 2 pages.
Bonow et al; “ACC/AHA 2006 Guidelines for the Management of Patients with Valvular Heart Disease,” Journal of American College of Cardiology, vol. 48(3): pp. e1-e148, 2006.
Boston Scientific, “Device Details.” Retrieved from the Internet: http://bostonscientific.com/med_specialty/deviceDetail.jsp, 1 page, [retrieved on Aug. 31, 2006.].
Braunberger et al; “Very Long-Term Results (More Than 20 years) of Valve Repair with Carpentier's Techniques in Nonrheumatic Mitral Valve Insufficiency,” Circulation, vol. 104, pp. I18-I11, 2001.
Braunwald et al; “Conservative Management of Tricuspid Regurgitation in Patients Undergoing Mitral Valve Replacement,” Circulation, vols. XXXV and XXXVI: pp. 163-169, 1967.
Carpentier et al; “Surgical Management of Acquired Tricuspid Valve Disease,” Journal of Thoracic and Cardiovascular Surgery, vol. 67(1): pp. 53-65, 1974.
Center for Devices and Radiological Health, U.S. Department of Health and Human Services Food and Drug Administration “Guidance for Annuloplasty Rings 510(k) Submissions; Final Guidance for industry and FDA Staff,” pp. 1-15, 2001.
Cosgrove et al; “Mitral Valvuloplasty,” Curro. Probl. Cardiology, pp. 349-405, 1989.
Dreyfus et al; “Secondary Tricuspid Regurgitation or Dilatation: Which Should Be the Criteria for Surgical Repair?,” Annual Thoracic Surgery, vol. 79, pp. 127-132, 2005.
Google Images, Recurved Hooks. Retrieved from the Internet: www.implementology.org.pf and personal .cityu.edu.hk, 1 page, [Retrieved on Dec. 14, 2006].
Leung et al; “Barbed, Bi-directional Surgical Sutures: In Vivo Strength and Histopathology Evaluations,” Society for Biomaterials 28th Annual Meeting Transactions, #724, 1 page, 2003.
Magovern et al; “Sutureless Artificial Heart Valves,” Circulation, vol. 27, pp. 784-788, 1963.
McCarthy et al; “Tricuspid Valve Repair: Durability and Risk Factors for Failure,” Journal of Thoracic and Cardiovascular Surgery, vol. 127, pp. 674-685, 2004.
Nath et al; “Impact of Regurgitation on Long-Term Survival,” Journal of American College of Cardiology, vol. 43, (3): pp. 405-409, 2004.
Navia et al; “Surgical Management of Secondary Tricuspid Valve Regurgitation: Annulus, Commissure, or Leaflet Procedure?,” Abstract presented at American Association for Thoracic Surgery Annual Meeting, 2009.
Rogers et al; “The Tricuspid Valve: Current Perspective and Evolving Management of Tricuspid Regurgitation,” Circulation, vol. 199, pp. 2718-2725, 2009.
Sagie et al; “Determinants of Functional Tricuspid Regurgitation in Incomplete Tricuspid Valve Closure: Doppler Color Flow Study of 109 Patients,” Journal of American College of Cardiology, vol. 24, pp. 446-453, 1994.
Savage et al; “Use of Mitral Valve Repair: Analysis of Contemporary United States Experience Reported to the Society of Thoracic Surgeons National Cardiac Database,” Annual Thoracic Surgery, vol. 75, pp. 820-825, 2003.
Shiran et al; Tricuspid Regurgitation in Mitral Valve Disease, Journal of the American College of Cardiology, vol. 53(5), pp. 401-408, 2009.
Song et al; “Factors Associated with Development of Late Significant Tricuspid Regurgitation after Successful Left-Sided Valve Surgery,” Heart, vol. 95, pp. 931-936, 2009.
Tang et al; “Tricuspid Valve Repair with an Annuloplasty Ring results in Improved Long-Term Outcomes,” Circulation, vol. 114, pp. 1577-1581, 2006.
Thompson “Percutaneous Heart Valve Technology: The Mitral Challenge,” Medtech Insight, vol. 11(2): pp. 38-52, 2009.
Zlotnick et al; “A Perfectly Functioning Magovern-Cromie Sutureless Prosthetic Aortic Valve 42 Years After Implantation,” Circulation, vol. 117: pp. e1-e2, 2008.
International Search Report and Written Opinion: Application No. PCT/US2013/059751; 8 pages, dated Dec. 11, 2013.
Extended European Search Report dated Jun. 13, 2016 in European Patent Application No. 13837432.7.
International Search Report and Written Opinion dated May 26, 2017 for PCT/US2017/016284.
International Search Report dated Oct. 8, 2015 for PCT/US2015/040622.
International Search Report dated Jul. 1, 2008 for PCT/US2008/050224.
International Search Report dated Jul. 13, 2010 for PCT/US2010/027943.
International Search Report dated Sep. 22, 2011 for PCT/US2011/039022.
International Search Report dated Dec. 7, 2011 for PCT/US2011/047345.
International Search Report dated Jul. 21, 2014 for PCT/US2014/026333.
International Search Report dated May 5, 2016 for PCT/US2016/017866.
International Search Report dated Apr. 19, 2017 for PCT/US16/062107.
Related Publications (1)
Number Date Country
20230077976 A1 Mar 2023 US
Provisional Applications (2)
Number Date Country
62291347 Feb 2016 US
61700989 Sep 2012 US
Continuations (2)
Number Date Country
Parent 17081128 Oct 2020 US
Child 17991790 US
Parent 15423374 Feb 2017 US
Child 17081128 US
Continuation in Parts (1)
Number Date Country
Parent 14427909 US
Child 15423374 US